Tags:BioTechDrugHumanLivingMedTech
Levicept Ltd is a UK-based biotechnology company developing a novel, safe and efficacious biological therapy (LEVI-04 [p75NTR-Fc]) for the treatment of chronic pain. The company is progressing LEVI-04 to phase I clinical trials to test its efficacy and safety in patients with osteoarthritis. With more than 1 billion people worldwide living with some type of chronic pain, a large unmet medical need for safe and effective analgesics exists. Traditional non-steroidal anti-inflammatory drugs (NSAIDs) are the most widely used drugs to treat pain and inflammation associated with osteoarthritis, but their use is limited by adverse effects on gastrointestinal and platelet function, as well as increased cardiovascular liability.
Location: United Kingdom, England, Sandwich
Member count: 11-50
Total raised: $20M
Founded date: 2012

Investors 2

Funding Rounds 1

DateSeriesAmountInvestorsDeal News
07.10.2014-$20M-gildehealt...

Mentions in press and media 2

DateTitleDescriptionCategoryAuthorSource
08.10.2014Levicept e...Pfizer's ($PFE) 2011 move to c...Venture Ca...-fiercebiot...
07.10.2014Levicept L...Sandwich, UK – Levicept Ltd., ...--gildehealt...